1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of the diagnosis-to-treatment interval (DTI) on outcomes in older adults with diffuse large B-cell lymphoma (DLBCL) treated in the real-world setting
    Meeting Abstract

    Hamlin, P. A.; Torka, P.; Hansen, E.; Belli, A. J.; Ambrose, J.; Zettler, C. M.; Fernandes, L. L.; Wiley, S.; Perry, B.; Wang, C. K.
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (RR) mantle-cell lymphoma (MCL) by race/ethnicity and TP53 mutation status
    Meeting Abstract

    Phillips, T. J.; Danilov, A. V.; Ruan, J.; Patel, K.; Kumar, A.; Wang, Y. C.; Maglinte, G. A.; Seymour, E.; Kamdar, M.
    Blood (2024)

    Fulltext@MSK | Save
  • An open-label, multi-center phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of stem cells in patients with multiple myeloma undergoing autologous stem cell transplant
    Meeting Abstract

    Caculitan, N.; Kim, G.; Woolfrey, A.; Akard, L. P.; Jeong, A. R.; Khouri, J.; Shah, G. L.; Cardarelli, P. M.
    Blood (2024)

    Fulltext@MSK | Save
  • Risk factors associated with sub-optimal outcomes following obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): What we have learned from the FELIX trial
    Meeting Abstract

    Roddie, C.; Park, J. H.; Shaughnessy, P.; Logan, A. C.; Sandhu, K. S.; Abedi, M.; Shah, B. D.; Bishop, M. R.; DeAngelo, D. J.; Brugger, W.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mitochondrial augmentation of hematopoietic stem and progenitor cells as a new therapeutic approach for myelodysplasia
    Meeting Abstract

    Fujino, T.; Avni, N.; Kutner, N.; Khoury, H.; Pozner, G.; Sabath, N.; Castro, C.; Fox, N.; Lewis, A. M.; Tittley, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Biomarker correlates and clinical activity of cevostamab in patients (pts) with triple-class refractory multiple myeloma (MM) who have received ≥1 prior B-cell maturation antigen (BCMA)-targeted bispecific antibody (BsAb): Results from the phase I/II CAMMA 2 study
    Meeting Abstract

    Delforge, M.; Richter, J.; Cohen, Y. C.; Corradini, P.; Sborov, D. W.; Lesokhin, A. M.; Berdeja, J. G.; Gatt, M. E.; Paris, L.; Dachs, L. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Radiation therapy in a new era of multiple myeloma management: Trends of engagement and radiologic, biochemical, and cytogenetic correlates of outcomes and response
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Usmani, S. Z.; Mailankody, S.; Imber, B. S.; Yahalom, J.
    Blood (2024)

    Fulltext@MSK | Save
  • MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Prince, H. M.; Bahlis, N. J.; Rodríguez-Otero, P.; Karlin, L.; Akard, L.; Varshavsky-Yanovsky, A.; Chu, M. P.; Nagai, Y.; Vesole, D. H.; Hickman, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save